Cover Image
Market Research Report

Pharma Leader Series: Top 55 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2020 - Financial Performances, Services, Capacities, Mergers & Acquisitions, SWOT Analysis

Published by Visiongain Ltd Product code 931011
Published Content info 265 Pages
Delivery time: 1-2 business days
Price
Back to Top
Pharma Leader Series: Top 55 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2020 - Financial Performances, Services, Capacities, Mergers & Acquisitions, SWOT Analysis
Published: January 16, 2020 Content info: 265 Pages
Description

Contract manufacturing represents the largest sector of the pharma outsourcing industry. Pharmaceutical companies have sought to take advantage of the benefits of contract manufacturing - lower costs, increased flexibility and external expertise - to focus resources on core competencies in drug development and marketing.

CMOs are increasingly seen as a strategic partner for pharmaceutical companies, providing a one-stop-shop of services for formulation development and manufacturing throughout the lifecycle of a drug.

The market leading CMOs have grown through acquisitions and site expansions to offer almost all required services on a global scale. However, there is still a role to be played by specialist CMOs, particularly those that offer biological drug manufacturing services.

This updated study discusses market-leading companies worldwide, as well as the strategies they have employed to develop in recent years. Visiongain's research and analysis explore opportunities and challenges for the top 55 pharma contract manufacturing organisations.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 265-page report you will receive 154 tables and 50 figures- all unavailable elsewhere.

The 265-page report provides clear detailed insight into the leading pharmaceutical contract manufacturing organizations. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Profiles of the 50 leading pharmaceutical contract manufacturing organizations:

  • AbbVie Contract Manufacturing
  • Aenova Group
  • Aesica Pharmaceuticals
  • Ajinomoto Althea, Inc.
  • Albany Molecular Research, Inc.
  • Alkermes plc
  • Almac Group
  • Amatsigroup
  • Aurobindo Pharma Ltd.
  • Avid Bioservices Inc.
  • Baxter Biopharma Solutions
  • Bayer AG
  • Biophore
  • Boehringer Ingelheim GmbH
  • Cambrex Corporation
  • Cardinal Health
  • Catalent Pharma Solutions Inc.
  • Charles River Laboratories International Inc.
  • Delpharm
  • Dr. Reddy's Laboratories Ltd.
  • Evonik Degussa
  • Famar Health Care Services
  • Fareva
  • Fujifilm Diosynth Biotechnologies UK Ltd.
  • GlaxoSmithKline plc
  • Huapont Medical
  • Lonza Group Ltd.
  • Nipro Corporation
  • Paragon Bioservices Inc
  • Patheon Inc
  • Pfizer Inc./Pfizer CentreSource (PCS)
  • Roche
  • Royal DSM NV
  • Strides
  • Teva API
  • Vetter Pharmacuticals
  • WuXi AppTec
  • Xcelience LLC
  • Xcellerex LLC
  • Zhejiang Hisun Pharmaceutical
  • Other Companies

The content of each profile differs, depending on the organization. In general, a profile gives the following information:

  • Overview of the company's contract manufacturing services and operations
  • Analysis of recent financial performance - annual revenue for CMO services, including some data on operating profit and margins
  • Assessment of developments - activities, acquisitions, production capacity, deals, new service offerings and collaborations
  • SWOT analysis - a firm's strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth

Key Questions Answered by This Report:

  • Who are the leading pharmaceutical contract manufacturers?
  • What factors are driving and restraining the growth for leading CMOs?
  • How have the leading CMOs performed financially in recent years?
  • Which CMOs will experience revenue growth over the coming years?
  • What are the strengths and weaknesses for the leading pharmaceutical CMOs?
  • How do leading CMOs compare in terms of production capacity and facilities?
  • What strategies have CMOs been implementing for sales growth in recent years?
  • Which technologies will be crucial to CMOs?

Visiongain's study is intended for anyone requiring commercial analyses for pharmaceutical contract manufacturing market. You find data, trends and predictions.

Buy our report today Pharma Leader Series: Top 55 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2020: Financial Performances, Services, Capacities, Mergers & Acquisitions, SWOT Analysis.

Visiongain is a trading partner with the US Federal Government.

Table of Contents
Product Code: PHA0667

Table of Contents

1. Report Overview

  • 1.1. Leading Contract Manufacturing Organisations(CMOs) Overview
  • 1.2. Benefits of This Report
  • 1.3. How This Report Delivers Information
  • 1.4. Main Questions This Report Answers
  • 1.5. Who is This Report For?
  • 1.6. Methods of Research and Analysis
  • 1.7. Frequently Asked Questions(FAQs)
  • 1.8. Some Associated Reports
  • 1.9. About Visiongain

2. Introduction to Pharmaceutical Contract Manufacturing, 2019

  • 2.1. What Services Do Contract Manufacturers Offer?
    • 2.1.1. Why Do Firms Outsource Manufacturing?
    • 2.1.2. What Is Driving Demand for Contract Manufacturing Services?
  • 2.2. The Pharmaceutical Contract Manufacturing Market, 2019
    • 2.2.1. Where is Supply and Demand Highest for Contract Manufacturing Services?
  • 2.3. Driving and Restrictive Forces for Pharmaceutical Contract Manufacturing
    • 2.3.1. Pharmaceutical Contract Manufacturing: Market Drivers
    • 2.3.2. Pharmaceutical Contract Manufacturing: Market Restraints

3. Leading Contract Manufacturing Organisations

  • 3.1. Alcami Corporation-A Contract Development and Manufacturing Organization
    • 3.1.1. Alcami: Manufacturing Services and Capabilities
    • 3.1.2. Divisional Segmentation-Breakdown of Alcami's Service
    • 3.1.3. Alcami Focuses on Advancing its Analytical Testing Turnaround Time
    • 3.1.4. Alcami Extended its Laboratory Service Program
    • 3.1.5. Alcami: Madison Dearborn Partners
    • 3.1.6. Alcami Expands its Sales Office
    • 3.1.7. Alcami Partnered with Solasia Pharma for Manufacturing Active Pharmaceutical Ingredient
  • 3.2. AbbVie Contract Manufacturing
    • 3.2.1. AbbVie Offers Full-Service Contract Manufacturing
    • 3.2.2. Expanding and Adding New Services: 2018-2019
    • 3.2.3. Biologics and HPAPIs Are Opportunities for Growth
  • 3.3. Aenova Group
    • 3.3.1. Acquisition of Haupt Creates European CMO Giant
    • 3.3.2. Aenova's Ever Expanding Manufacturing Capacity
    • 3.3.3. Aenova's Competitive Position in the Contract Manufacturing Market: SWOT Analysis
    • 3.3.4. Aenova: New Manufacturing Facilities to Expand Geographic Presence
  • 3.4. Aesica Pharmaceuticals
    • 3.4.1. Aesica Manufactures APIs and Finished Dosage Forms
    • 3.4.2. Acquisitions Drive Revenue Growth
    • 3.4.3. Partnering with Academia for Innovative Solutions
    • 3.4.4. Growth through Acquisitions and Internal Expansion
    • 3.4.5. Aesica: Opportunities for Expansion
  • 3.5. Ajinomoto Althea, Inc.
    • 3.5.1. Ajinomoto Althea Expands its Manufacturing Capabilities
    • 3.5.2. Ajinomoto: New U.S. Patent for Manufacturing Crystal Monoclonal Antibodies
    • 3.5.3. Ajinomoto Althea Expanding its Manufacturing Capacity
  • 3.6. Albany Molecular Research, Inc.
    • 3.6.1. Acquiring New Businesses to Expand Capabilities and Services
    • 3.6.2. Expanding Business Operations in New Geographies
    • 3.6.3. Collaborations to Enhance Services
    • 3.6.4. AMRI Acquisition of Euticals S.p.a
  • 3.7. Alkermes
    • 3.7.1. Collaboration as a Growth Strategy to Develop and Commercialize Products
    • 3.7.2. Alkermes: Clinical Development Program
  • 3.8. Almac Group
    • 3.8.1. Almac's Manufacturing Services
    • 3.8.2. Almac Adding Capacity Globally
    • 3.8.3. New Services Added
    • 3.8.4. Almac Group: Contract Manufacturing Market Outlook
  • 3.9. Amatsigroup(Eurofin Amtasigroup)
    • 3.9.1. Amatsi: Contract Manufacturing Agreement
    • 3.9.2. Mergers and Acquisitions to Enhance Market Presence
    • 3.9.3. Amatsigroup Expands its Operations and Product Portfolio
  • 3.10. Aurobindo Pharma
    • 3.10.1. API Manufacturing Services
    • 3.10.2. Aurobindo Pharma: Steady Revenue Growth 2012-2017
    • 3.10.3. Aurobindo Expanding Outside of Antibacterial
    • 3.10.4. Aurobindo: Opportunities for Expansion
  • 3.11. Avid Bioservices, Inc.
    • 3.11.1. Avid Focuses on Expanding its Manufacturing Capacity
    • 3.11.2. Avid Bioservices Selected by Acumen Pharmaceuticals to Lead Process Development and Clinical Manufacture
    • 3.11.3. Avid Bioservices Expands Process Development Capabilities and Laboratory Infrastructure
  • 3.12. Bayer Healthcare AG
    • 3.12.1. Bayer Focuses on Providing Superior Pharmaceutical Services
    • 3.12.2. Bayer Focuses Quality for all the Products and Services Offered by the Company
    • 3.12.3. Bayer Pharmaceuticals main focus areas
    • 3.12.4. Bayer's Vision 2020
  • 3.13. Baxter BioPharma Solutions
    • 3.13.1. BioPharma Solutions Offers a Broad Product Portfolio of Sterile Contract Manufacturing Services and Solutions
    • 3.13.2. BioPharma Focuses on Expanding its Manufacturing Capacities
    • 3.13.3. Baxter BioPharma Solutions and SAFC Collaborate on Complete ADC Offering
    • 3.13.4. Baxter BioPharma Solutions Focuses on Research & Development Investments
    • 3.13.5. Baxter BioPharma is the Global Leader in Sterile Fill and Finish
    • 3.13.6. Baxter BioPharma SWOT Analysis
  • 3.14. Biomay AG
    • 3.14.1. Biomay Offers Fully Integrated GMP Capacities
    • 3.14.2. Biomay Focuses on Increasing its Capital
  • 3.15. Boehringer Ingelheim Contract Manufacturing
    • 3.15.1. BI Existing Units and Expansion to new areas
    • 3.15.2. Production Through to Fill and Finished Biopharmaceuticals
    • 3.15.3. A Track Record of Production for 29 Biopharma Products
    • 3.15.4. Increasing Revenue from Contract Manufacturing, 2012-2019
    • 3.15.5. Pulling Out of Small Molecule API Manufacturing
    • 3.15.6. Expanding through New Services
    • 3.15.7. Boehringer Ingelheim Biopharmaceuticals: Opportunities for Growth
  • 3.16. Catalent Pharma Solutions-the World's Leading CMO
    • 3.16.1. Catalent: Manufacturing Services and Capabilities
    • 3.16.2. Divisional Segmentation-Catalent's Service
    • 3.16.3. Catalent Pharma's Revenue Growth, 2014-2019
    • 3.16.4. Catalent Is Expanding its Softgel Technologies Division
    • 3.16.5. Quadrupling Biopharmaceutical Manufacturing Capacity
    • 3.16.6. Expansion of Packaging Services in Asia-Pacific and Europe: 2018
    • 3.16.7. Adding New Early-Stage Development Services
    • 3.16.8. Expansion in Japan-Growth Prospects for Catalent
    • 3.16.9. New Business Contracts 2014-2019
    • 3.16.10. Catalent: Opportunities for Growth
  • 3.17. Charles River Laboratories International, Inc.
    • 3.17.1. Charles River Laboratories Focuses on Increasing the Service Areas of its Offerings
    • 3.17.2. Strategic Acquisitions as a Growth Strategy to Expand Product Portfolio
    • 3.17.3. Charles River Laboratories Revenue Growth, 2013-2018
  • 3.18. Cardinal Health, Inc.
    • 3.18.1. Cardinal Health Focuses on Helping Healthcare Organizations for Patient Safety
    • 3.18.2. Cardinal Revenue Growth, 2013-2018
  • 3.19. CordenPharma International
    • 3.19.1. CordenPharma Service Division
    • 3.19.2. CordenPharma Emerging in the API Market
    • 3.19.3. Investments in Highly Potent Capabilities
    • 3.19.4. CordenPharma: SWOT Analysis
  • 3.20. Daito Pharmaceutical Co., Ltd.
    • 3.20.1. Daito Has a Portfolio of More than 43 APIs
    • 3.20.2. Rapid Growth in Revenue and Operational Profit: Daito Financial Performance 2013-2018
    • 3.20.3. Daito Is Well-Placed for Asian Market Growth-SWOT Analysis
  • 3.21. Delpharm
    • 3.21.1. Finished Dosage Form Manufacturing for Developed Markets
    • 3.21.2. Delpharm: Rapid Revenue Growth Via Acquisitions, 2013-2019
    • 3.21.3. Delpharm: Outlook and Prospects for Growth
  • 3.22. Divis Laboratories
    • 3.22.1. Divis Laboratories and the Contract Manufacturing Industry
    • 3.22.2. Divis Laboratories: A Rapidly Growing CMO, 2014-2019
    • 3.22.3. Divis Laboratories: API Manufacturing
  • 3.23. Dr. Reddy's Laboratories Ltd.
    • 3.23.1. API and FDF Manufacturing Services
    • 3.23.2. Dr. Reddy's PSAI: Strong Revenue Growth 2012-2017
    • 3.23.3. Advancing in Complex Drug Manufacturing
    • 3.23.4. Expanding in the European Manufacturing Market
  • 3.24. DPT Laboratories, Ltd.
    • 3.24.1. Mylan Acquires Topicals-Focused Specialty and Generic Business of DPT
    • 3.24.2. DPT Enhances Flexibility and Efficiencies
    • 3.24.3. DPT Enhances Capabilities with New High-Speed Filling Center
  • 3.25. Esteve Qu`mica
    • 3.25.1. Esteve Química Manufactures APIs for Developed and Emerging Markets
    • 3.25.2. Expanding in the US, 2018
    • 3.25.3. Esteve Química: SWOT Analysis
  • 3.26. Evonik Degussa
    • 3.26.1. Investing in API and Drug Delivery Services
    • 3.26.2. Moderate Growth in Pharmaceutical Manufacturing Services, 2013-2018
    • 3.26.3. Evonik Is a HPAPI Specialist
    • 3.26.4. Evonik Continues to Grow Across All Segments
    • 3.26.5. How Can Evonik Expand in the Pharmaceutical Contract Manufacturing Market?
  • 3.27. FAMAR Health Care Services
    • 3.27.1. Famar Is an Expert in Lyophilisation
    • 3.27.2. Sustained Growth in Famar's Revenue
    • 3.27.3. Expanding Outside Europe
    • 3.27.4. Further Site Acquisitions Are an Opportunity for Growth
  • 3.28. Fareva Group
    • 3.28.1. Fareva Has 35 Years' Manufacturing Experience
    • 3.28.2. Revenue Growth through Acquisitions:
    • 3.28.3. Fareva SWOT Analysis
  • 3.29. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
    • 3.29.1. Opening of New Manufacturing facility
    • 3.29.2. Fujifilm Establishes Cell Culture Process Development Laboratories
    • 3.29.3. Fujifilm Completes Acquisition of Kalon Biotherapeutics LLC
  • 3.30. GlaxoSmithKline plc
    • 3.30.1. GSK Enters into an Agreement with Novartis for Full Ownership of Consumer Healthcare Business
    • 3.30.2. GSK Received Complete Response from FDA for Candidate Pandemic H5N1 Adjuvanted Influenza Vaccine
  • 3.31. Pfizer CentreOne
    • 3.31.1. Pfizer CentreSource: Historic Revenue Performance, 2012-2017
    • 3.31.2. Will Hospira Acquisition Lead to Revenue Growth in Future?
  • 3.32. Huapont Pharmaceutical Co., Ltd.
    • 3.32.1. China Pharmaceutical Trade
  • 3.33. Lonza
    • 3.33.1. Lonza Is a Leader in Biologics Manufacturing
    • 3.33.2. Lonza Contract Manufacturing and Development
    • 3.33.3. Investing in Advanced Biological Drug Sectors
    • 3.33.4. The Promise of Antibody-Drug Conjugates(ADCs)
    • 3.33.5. The Regenerative Medicine Future in Japan
    • 3.33.6. Lonza: SWOT Analysis
  • 3.34. Nipro Corporation: Japan's Leading CMO
    • 3.34.1. Nipro Pharmaceutical Contract Manufacturing Capabilities
    • 3.34.2. Nipro Revenues 2014-2019
    • 3.34.3. Biosimilars and Anti-Cancer Drugs Are Opportunities for Future Growth: SWOT Analysis
  • 3.35. Paragon Bioservices, Inc.
    • 3.35.1. Paragon Announced Expansion of its New Manufacturing Facility
  • 3.36. Patheon-One of the Top 3 CMOs
    • 3.36.1. Patheon-Global leader in Pharmaceutical Development Services
    • 3.36.2. Contract Manufacturing Services at Patheon
    • 3.36.3. Steady Revenue Growth 2012-2017
    • 3.36.4. DPx Holdings: Developments
    • 3.36.5. Adding New Formulations and Formulation Development Services
    • 3.36.6. Expanding Services Through Acquisition, 2016
    • 3.36.7. Patheon: SWOT Analysis
  • 3.37. Recipharm
    • 3.37.1. Contract Development and Manufacturing Services
    • 3.37.2. Recipharm: Financial Performance 2013-2018
    • 3.37.3. Recipharm Invests in Facility Expansion
    • 3.37.4. Recipharm Growing in the Development and Technology Market Through Acquisitions
    • 3.37.5. Recipharm: SWOT Analysis
  • 3.38. F. Hoffman-La Roche Ltd.
    • 3.38.1. Amplified Revenue Growth in Pharma Manufacturing 2012-2017
    • 3.38.2. Value of Innovation
    • 3.38.3. Approvals and Extensions in Pharmaceuticals Division
    • 3.38.4. Launch of New Products Drive the Growth of the Company
  • 3.39. Royal DSM
    • 3.39.1. Amplified Revenue Growth in Pharma Manufacturing 2013-2018
    • 3.39.2. DSM Pharmaceuticals Products/DPx Holdings: Manufacturing Services
    • 3.39.3. DSM Sinochem Pharmaceuticals: A World Leader in Antibacterial Manufacturing
    • 3.39.4. DPx Holdings: A New Pharma Leader
    • 3.39.5. Investing in Biopharma Manufacturing
    • 3.39.6. Expanding API Manufacturing
    • 3.39.7. Generics and Biologics Offer Room for Growth
  • 3.40. Shandong Xinhua Pharmaceutical
    • 3.40.1. Experience in APIs and Finished Dosage Forms
    • 3.40.2. Shandong Xinhua: Strong Revenue Growth 2013-2018
    • 3.40.3. Growing through Joint Ventures
    • 3.40.4. Looking to Expand in the US and EU
  • 3.41. Siegfried
    • 3.41.1. Siegfried's Acquisitions, 2013-2019
    • 3.41.2. Expanding Siegfried's Manufacturing Footprint Globally
    • 3.41.3. Expanding High Potency API Capabilities
    • 3.41.4. Siegfried: Financial Performance 2013-2018
    • 3.41.5. Siegfried's Characteristics within the Contract Manufacturing Market: SWOT Analysis
  • 3.42. TEVA Pharmaceutical, Ltd.
    • 3.42.1. API Manufacturing Services
    • 3.42.2. Teva API: Financial Performance 2012-2017
    • 3.42.3. Building a Footprint in Mexico, India and China
    • 3.42.4. Teva API: SWOT Analysis
  • 3.43. Therapure Biopharma, Inc.
    • 3.43.1. Therapure Collaborated with 3SBio Inc., and CPE Funds
  • 3.44. UPM Pharmaceuticals
  • 3.45. Vetter Pharmaceutical
    • 3.45.1. Vetter is an Injectable Manufacturing Specialist
    • 3.45.2. Services, Collaborations and Differentiating Factors
    • 3.45.3. Expanding Services in the US and Asia
    • 3.45.4. Biologics: Opportunity for Growth for Vetter
  • 3.46. Xcelience, LLC
  • 3.47. Xcellerex, Inc.
  • 3.48. Piramal Pharma Solutions
    • 3.48.1. Mergers and Acquisitions
    • 3.48.2. Piramal Pharma Solutions: Financial Performance 2013-2018
    • 3.48.3. Investment in Technology based Delivery Platforms
    • 3.48.4. Quality Governance
  • 3.49. Zhejiang Hisun Pharmaceutical
    • 3.49.1. API Manufacturing for Markets Worldwide
    • 3.49.2. Moving into International Drug Marketing
    • 3.49.3. Zhejiang Hisun: Opportunities for Growth
  • 3.50. Zhejiang Huahai Pharmaceuticals
    • 3.50.1. Zhejiang Huahai Is a Market Leader Within the Antihypertensive API Market
    • 3.50.2. Zhejiang Huahai: Contract Manufacturing Performance 2012-2017
    • 3.50.3. Expanding in the US Generic Drugs Market
    • 3.50.4. Zhejiang Huahai: SWOT Analysis
  • 3.51. Cambrex Corporation
    • 3.51.1. Cambrex acquisition by Permira in 2019
    • 3.51.2. Revenue growth of Cambrex Corporation 2014-2018
    • 3.51.3. Cambrex Corporation SWOT Analysis
  • 3.52. WuXi Pharma tech
    • 3.52.1. WuXi Tech strategies for development
    • 3.52.2. WuXi Tech SWOT analysis
  • 3.53. Biocon
    • 3.53.1. Biocon Revenue Analysis 2013-2018
    • 3.53.2. Merger and Acquistion a leading strategy for Biocon
    • 3.53.3. SWOT Analysis of Biocon
  • 3.54. Strides
    • 3.54.1. Revenue of Stride 2014-2019
    • 3.54.2. Strides-SWOT Analysis
  • 3.55. Biophore
    • 3.55.1. Biophore Developemnt in API production

4. Conclusions of the Study

  • 4.1. What Has Driven Growth for CMO Market Leaders in Recent Years?
  • 4.2. Strategies for Growth: Prospects for Leading CMOs
  • 4.3. High Demand for Biopharmaceutical Manufacturing Services
  • 4.4. Investing in Novel Technologies
  • 4.5. Outlook for API Manufacturers

Appendices

  • Some Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 2.1: Benefits and Drawbacks to Outsourcing Pharmaceutical Manufacturing, 2020
  • Table 2.2: Contract Manufacturing Market Total Revenue: Total Revenue($bn), Annual Growth(%), 2016-2018
  • Table 2.3: Contract Manufacturing Market by Leading Country: Market Size($bn), Market Share(%), 2018
  • Table 3.1: Alcami Details
  • Table 3.2: Alcami Facility Details
  • Table 3.3: AbbVie Contract Manufacturing: Details
  • Table 3.4: AbbVie Contract Manufacturing Facility Capabilities
  • Table 3.5: AbbVie Contract Manufacturing SWOT Analysis
  • Table 3.6: Aenova Group Details
  • Table 3.7: Aenova Group Manufacturing Capacity by Dosage Form
  • Table 3.8: Aenova Group Manufacturing Facility Details
  • Table 3.9: Aenova Group SWOT Analysis
  • Table 3.10: Aesica Details
  • Table 3.11: Aesica Pharmaceuticals: Revenue($m), Operating Profit($m), Operating Margin(%), Annual Growth Rates(%), CAGRs(%), 2014-2019
  • Table 3.12: Aesica SWOT Analysis
  • Table 3.13: Ajinomoto Althea, Inc. Details
  • Table 3.14: Albany Molecular Research, Inc. Details
  • Table 3.15: Alkermes Details
  • Table 3.16: Almac Details
  • Table 3.17: Almac Pharmaceutical Manufacturing Facilities Details
  • Table 3.18: Almac: SWOT Analysis
  • Table 3.19: Amatsigroup Details
  • Table 3.20: Aurobindo Pharma Details
  • Table 3.21: Aurobindo Contract Manufacturing: Revenue($m), Annual Growth Rate(%), CAGR(%), 2014-2018
  • Table 3.22: Aurobindo Contract Manufacturing: SWOT Analysis
  • Table 3.23: Avid Bioservices, Inc. Details
  • Table 3.24: Bayer Healthcare AG Details
  • Table 3.25: Baxter BioPharma Solutions Details
  • Table 3.26: Baxter BioPharma Solutions: Facilities and Services Offered
  • Table 3.27: Baxter BioPharma Solutions SWOT Analysis
  • Table 3.28: Biomay AG Details
  • Table 3.29: Boehringer Ingelheim Biopharmaceuticals Details
  • Table 3.30: Boehringer Ingelheim Total Pharmaceutical Manufacturing Capacity: Reactor Size and Number of Units by CMO Service
  • Table 3.31: Products Developed by Boehringer Ingelheim Biopharmaceuticals, 1983-2014
  • Table 3.32: Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue($m), Annual Growth(%), CAGR(%), 2013-2018
  • Table 3.33: Boehringer Ingelheim: SWOT Analysis
  • Table 3.34: Catalent Details
  • Table 3.35: Catalent Facility Details
  • Table 3.36: Catalent Financial Performance: Revenue($m), Annual Growth Rates(%), CAGR(%), 2014-2019
  • Table 3.37: Catalent Financial Performance by Product Type: Revenue($m), Revenue Share(%), 2019
  • Table 3.38: Catalent Pharma SWOT Analysis
  • Table 3.39: Charles River Laboratories International, Inc. Details
  • Table 3.40: Charles River Financial Performance: Revenue($m), Annual Growth Rates(%), CAGR(%), 2013-2018
  • Table 3.41: Cardinal Health, Inc. Details
  • Table 3.42: Cardinal Health Financial Performance: Revenue($b), Annual Growth Rates(%), CAGR(%), 2013-2018
  • Table 3.43: CordenPharma International Details
  • Table 3.44: CordenPharma Facilities and Service Details
  • Table 3.45: CordenPharma SWOT Analysis
  • Table 3.46: Daito Pharmaceutical: Details
  • Table 3.47: Daito Pharmaceuticals Financial Performance: Revenue($m), Revenue(¥m), CAGR(%), 2013-2018
  • Table 3.48: Daito Pharmaceuticals SWOT Analysis
  • Table 3.49: Delpharm Details
  • Table 3.50: Delpharm: Facilities and Services
  • Table 3.51: Delpharm: Revenue($m), Annual Growth Rate(%), CAGR(%), 2014-2018
  • Table 3.52: Delpharm: SWOT Analysis
  • Table 3.53: Divis Laboratories Details
  • Table 3.54: Divis Laboratories: Facility Details, Production Capacity and Services
  • Table 3.55: Divis Laboratories: Revenue($m), Annual Growth Rate(%), CAGR(%), 2013-2018
  • Table 3.56: Divis Laboratories Revenue Distribution: Revenue($m), Share of Total(%), 2018
  • Table 3.57: Divis Laboratories Revenue by Region: Revenue($m), Share of Total(%), 2018
  • Table 3.58: Divis Laboratories Contract Manufacturing: SWOT Analysis
  • Table 3.59: Dr. Reddy's Laboratories Ltd. Details
  • Table 3.60: Dr. Reddy's Laboratories Cumulative Drug Master File(DMF) Applications: Applications Accepted by Region, Regional Share(%), 2017
  • Table 3.61: Dr. Reddy's Laboratories Contract Manufacturing: Revenue($m), Annual Growth Rate(%), CAGR(%), 2015-2019
  • Table 3.62: Dr. Reddy's Laboratories: Contract Manufacturing Revenue($m) by Regional Market and Revenue Share(%), FY 2019
  • Table 3.63: Dr. Reddy's Laboratories: SWOT Analysis
  • Table 3.64: DPT Laboratories Ltd. Details
  • Table 3.65: Esteve Química Details
  • Table 3.66: Esteve Química SWOT Analysis
  • Table 3.67: Evonik Degussa Details
  • Table 3.68: Evonik Health and Nutrition: R&D and Production Sites by Region, 2018
  • Table 3.69: Evonik Pharmaceutical Manufacturing: Revenue($m), Annual Growth(%), CAGR(%), 2013-2018
  • Table 3.70: Evonik Pharmaceutical Manufacturing: SWOT Analysis
  • Table 3.71: Famar Details
  • Table 3.72: Famar Pharmaceutical Manufacturing Facilities
  • Table 3.73: Famar Pharmaceutical Manufacturing: Revenue($m), Annual Growth Rate(%), CAGR(%), 2013-2018
  • Table 3.74: Famar: SWOT Analysis
  • Table 3.75: Fareva Details
  • Table 3.76: Fareva Manufacturing Facilities
  • Table 3.77: Fareva Pharmaceutical Manufacturing: Revenue($m), Annual Growth Rate(%), CAGR(%), 2013-2018
  • Table 3.78: Fareva: SWOT Analysis
  • Table 3.79: FUJIFILM Diosynth Biotechnologies U.S.A., Inc. Details, 2017
  • Table 3.80: GlaxoSmithKline plc Details
  • Table 3.81: Pfizer CentreOne Details
  • Table 3.82: Pfizer CentreSource: Revenue($m), Annual Growth Rate(%), CAGR(%), 2012-2017
  • Table 3.83: Pfizer CentreOne SWOT Analysis
  • Table 3.84: Huapont Pharmaceutical Co., Ltd. Details
  • Table 3.85: Lonza Details
  • Table 3.86: Selected Lonza Pharmaceutical and Biotech Manufacturing and Development Agreements
  • Table 3.87: Lonza Pharma & Biotech Department: Revenue($m), 2013-2018
  • Table 3.88: ADCs Approved and in Late Stage Clinical Development
  • Table 3.89: Lonza SWOT Analysis, 2019
  • Table 3.90: Nipro Pharma Details
  • Table 3.91: Nipro Pharmaceutical Contract Manufacturing Capabilities: 2012-2017
  • Table 3.92: Nipro Pharmaceutical Contract Manufacturing: Annual Production Capacity, 2018
  • Table 3.93: Nipro Pharmaceutical Contract Manufacturing Financial Performance: Revenue($m), Annual Growth Rates(%), CAGR(%), 2014-2019
  • Table 3.94: Nipro Pharmaceutical Contract Manufacturing SWOT Analysis
  • Table 3.95: Paragon Bioservices, Inc. Details
  • Table 3.96: Patheon Details
  • Table 3.97: Patheon Manufacturing Facilities
  • Table 3.98: Patheon Pharmaceutical Manufacturing: Revenue($m), Annual Growth Rates(%), CAGRs(%), 2012-2017
  • Table 3.99: Patheon: SWOT Analysis
  • Table 3.100: Recipharm Details
  • Table 3.101: Recipharm: Facility Details and Services
  • Table 3.102: Recipharm: Revenue($m), Annual Growth Rates(%), CAGRs(%), 2013-2018
  • Table 3.103: Recipharm Manufacturing Revenue by Client Size: Revenue($m), Share of Total Revenues(%), 2018
  • Table 3.104: Recipharm Manufacturing Revenue Distribution: Customer Revenue($m), Share of Total Revenues(%), 2018
  • Table 3.105: Recipharm: SWOT Analysis
  • Table 3.106: F. Hoffman-La Roche Details
  • Table 3.107: Roche Pharmaceutical Manufacturing: Revenue($bn), Annual Growth(%), CAGR(%) 2013-2018
  • Table 3.108: Royal DSM Details
  • Table 3.109: Royal DSM Pharmaceutical Manufacturing: Revenue($m), Annual Growth(%), CAGR(%) 2012-2018
  • Table 3.110: DSM Pharmaceutical Products(DPP)/DPx Holdings Division: Revenue($m), Annual Growth(%), CAGR(%), 2011-2016
  • Table 3.111: DSM Sinochem Pharmaceuticals(DSP): Revenue($m), Annual Growth(%), CAGR(%), 2012-2017
  • Table 3.112: DSM Pharmaceutical Manufacturing: SWOT Analysis
  • Table 3.113: Shandong Xinhua Pharmaceuticals Details
  • Table 3.114: Shandong Xinhua Pharmaceutical Production Capacity by Dosage Form, 2018
  • Table 3.115: Shandong Xinhua: Revenue($m), Annual Growth Rate(%), CAGR(%), 2013-2018
  • Table 3.116: Shandong Xinhua Revenue Share by Geographic Region: Revenue Share(%), 2018
  • Table 3.117: Shandong Xinhua Manufacturing: SWOT Analysis
  • Table 3.118: Siegfried Details
  • Table 3.119: Siegfried Pharmaceutical Manufacturing Facilities Details, 2018
  • Table 3.120: Siegfried Pharmaceutical Manufacturing: Revenue($m), Annual Growth Rates(%), CAGRs(%), 2013-2018
  • Table 3.121: Siegfried: SWOT Analysis
  • Table 3.122: Teva API Details
  • Table 3.123: Teva API: Revenue($m), Annual Growth Rate(%), CAGR(%), 2012-2017
  • Table 3.124: Teva API SWOT Analysis
  • Table 3.125: Therapure Biopharma Details
  • Table 3.126: UPM Pharmaceuticals Details
  • Table 3.127: Vetter Details
  • Table 3.128: Vetter Pharmaceutical Facilities
  • Table 3.129: Vetter: SWOT Analysis
  • Table 3.130: Xcelience LLC Details
  • Table 3.131: Xcellerex, Inc. Details
  • Table 3.132: Piramal Pharma Solutions Details
  • Table 3.133: Piramal Pharma Solutions: Revenue($m), Annual Growth Rate(%), CAGR(%), 2014-2019
  • Table 3.134: Zhejiang Hisun Pharmaceuticals Details
  • Table 3.135: Zhejiang Hisun Manufacturing: SWOT Analysis
  • Table 3.136: Zhejiang Huahai Pharmaceuticals Details
  • Table 3.137: Zhejiang Huahai Contract Manufacturing: Revenue($m), Annual Growth Rate(%), CAGR(%), 2013-2018
  • Table 3.138: Zhejiang Huahai Contract Manufacturing: SWOT Analysis
  • Table 3.139: Cambrex Corporation Details
  • Table 3.140: Cambrex Corporation: Revenue($m), Annual Growth Rate(%), CAGR(%), 2013-2018
  • Table 3.141: Cambrex Corporation: SWOT Analysis
  • Table 3.142: WuXi Tech Details
  • Table 3.143: WuXi Tech: SWOT Analysis
  • Table 3.144: WuXi Tech Details
  • Table 3.145: Biocon: Revenue($m), Annual Growth Rate(%), CAGR(%), 2013-2018
  • Table 3.146: Biocon(Syngene International): SWOT Analysis
  • Table 3.147: Strides Details
  • Table 3.148: Strides: Revenue($m), Annual Growth Rate(%), CAGR(%), 2013-2018
  • Table 3.149: Stride: SWOT Analysis
  • Table 3.150: biophore India Pharmceutical Limited Details
  • Table 4.1: Top Five Developed and Emerging Market CMOs: Grouped Revenue($m), Annual Growth Rate(%), CAGR(%), 2012-2017

List of Figures

  • Figure 2.1: Selected Services Contracted to CMOs by Developmental Stage, 2018
  • Figure 2.2: Contract Manufacturing Market Total Revenue: Total Revenue($bn), 2016-2018
  • Figure 2.3: Contract Manufacturing Market by Leading Country: Market Share(%), 2018
  • Figure 2.4: Pharmaceutical Contract Manufacturing: Drivers and Restraints
  • Figure 3.1: Aesica Pharmaceuticals: Revenue($m), 2014-2019
  • Figure 3.2: Aurobindo Contract Manufacturing: Revenue($m), 2014-2018
  • Figure 3.3: Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue($m), 2013-2018
  • Figure 3.4: Catalent Facilities by Region, 2018
  • Figure 3.5: Catalent Facilities by Service Offered, 2018
  • Figure 3.6: Catalent Financial Performance: Revenue($m), 2014-2019
  • Figure 3.7: Catalent Financial Performance by Product Type: Revenue Share(%), 2019
  • Figure 3.7: Charles River Laboratories Financial Performance: Revenue($m), 2013-2018
  • Figure 3.8: Cardinal Health Financial Performance: Revenue($b), 2013-2018
  • Figure 3.9: Daito Pharmaceuticals Financial Performance: Revenue($m), 2013-2019
  • Figure 3.10: Delpharm: Revenue($m), 2014-2018
  • Figure 3.11: Divis Laboratories Contract Manufacturing: Revenue($m), 2013-2019
  • Figure 3.12: Divis Laboratories Revenue Distribution: Revenue($m), 2018
  • Figure 3.13: Divis Laboratories Revenue by Region: Share of Total(%), 2018
  • Figure 3.14: Dr. Reddy's Laboratories Cumulative Drug Master File(DMF) Applications: Accepted by Region(%), 2017
  • Figure 3.15: Dr. Reddy's Laboratories Contract Manufacturing: Revenue($m), 2015-2019
  • Figure 3.16: Dr. Reddy's Laboratories Contract Manufacturing Revenue: Regional Revenue Share(%), FY 2019
  • Figure 3.17: Evonik Health and Nutrition: R&D and Production Sites(%) by Region, 2018
  • Figure 3.18: Evonik Pharmaceutical Manufacturing: Revenue($m), 2013-2018
  • Figure 3.19: Famar Pharmaceutical Manufacturing: Revenue($m), 2013-2018
  • Figure 3.20: Fareva Pharmaceutical Manufacturing: Revenue($m), 2013-2018
  • Figure 3.21: Pfizer CentreOne: Revenue($m), 2012-2017
  • Figure 3.22: Lonza Pharma & Biotech: Revenue($m), 2013-2018
  • Figure 3.23: Lonza Custom Manufacturing by Regional Market: Revenue Share(%), 2019
  • Figure 3.24: Nipro Pharmaceutical Contract Manufacturing Capabilities: Orally Administered Drugs, Injectables, External Preparations, 2012-2017
  • Figure 3.25: Nipro Pharmaceuticals Financial Performance: Revenue($m), 2014-2019
  • Figure 3.26: Patheon Pharmaceutical Development Projects(%) by Phase, 2017
  • Figure 3.27: Patheon Pharmaceutical Manufacturing Projects by Client Size: Proportion of Total Revenue(%), 2019
  • Figure 3.28: Patheon Pharmaceutical Manufacturing: Revenue($m), 2012-2017
  • Figure 3.29: Recipharm: Revenue($m), 2013-2018
  • Figure 3.30: Recipharm Manufacturing Revenue by Client: Share of Total Revenues(%), 2018
  • Figure 3.31: Recipharm Manufacturing Revenue Distribution: Customer Revenue($m), 2018
  • Figure 3.32: Roche Pharmaceutical Manufacturing: Revenue($b), 2013-2018
  • Figure 3.33: Royal DSM Pharmaceutical Manufacturing: Revenue($m), 2013-2018
  • Figure 3.34: DSM Pharmaceutical Products(DPP)/ DPx Holdings Division: Revenue($m), 2011-2016
  • Figure 3.35: DSM Sinochem Pharmaceuticals(DSP): Revenue($m), 2012-2017
  • Figure 3.36: Shandong Xinhua: Revenue($m), 2013-2018
  • Figure 3.37: Shandong Xinhua Revenue Share by Geographic Region: Revenue Share(%), 1H 2018
  • Figure 3.38: Siegfried Pharmaceutical Manufacturing: Revenue($m), 2013-2018
  • Figure 3.39: Teva API: Revenue($m), 2012-2017
  • Figure 3.40: Piramal Pharma Solutions: Revenue($m), 2014-2019
  • Figure 3.41: Zhejiang Huahai Contract Manufacturing: Revenue($m), 2013-2018
  • Figure 3.42: Cambrex Corporation: Revenue($m), Annual Growth Rate(%), 2013-2018
  • Figure 3.43: Biocon(Syngene International): Revenue($m), Annual Growth Rate(%), 2013-2018
  • Figure 3.44: Strides: Revenue($m), Annual Growth Rate(%),2014-2019
  • Figure 4.1: Top Five Developed and Emerging Market CMOs: Grouped Revenue($m), 2012-2017

List of Companies Mentioned in the Report:

  • 3SBio Inc.
  • Abbott
  • AbbVie
  • Accucaps Industries Limited
  • Acorda
  • Activa Capital
  • Acumen Pharmaceuticals, Inc.
  • AdAlta
  • Adamas Pharmaceuticals
  • Aenova Group
  • Aesica Pharmaceuticals
  • Agennix
  • Agere Pharmaceuticals
  • Ajinomoto Althea, Inc.
  • Albany Molecular Research, Inc.
  • Alcami Corporation
  • Alkermes plc
  • Alliance Medical Products(AMP)
  • Almac Group
  • Althea Technologies Inc.
  • Amatsigroup
  • AmatsiQBiologicals
  • AMYRA Biotech
  • Apexigen
  • arGEN-X
  • Astellas Pharma
  • AstraZeneca
  • Athera Biotechnologies
  • Aurobindo Pharma Ltd.
  • Avalanche Biotechnologies
  • Avepharm
  • Avid Bioservices Inc.
  • Avogadro
  • Banner Life Sciences
  • Baxter Biopharma Solutions
  • Bayer AG
  • BC Partners
  • Biogen
  • Biomay AG
  • Bionomics
  • Biophore
  • Biotest
  • Boehringer Ingelheim BioXcellence
  • Boehringer Ingelheim GmbH
  • Breckenridge Pharmaceutical
  • Bristol-Myers Squibb
  • Cambrex Corporation
  • Cambridge Major Laboratories, Inc.
  • Carbogen Amcis
  • Cardinal Health
  • Catalent Pharma Solutions Inc.
  • Catalyst Capital Group, Inc.
  • Celladon
  • Celldex Therapeutics
  • Celsion
  • CEVEC Pharmaceuticals
  • Charles River Laboratories International Inc.
  • Chemisch-Pharmazeutisches Laboratorium Ravensburg
  • Chemtrix
  • Chongqing Huapont Pharmaceutical Co., Ltd.
  • Circadian Technologies
  • CITICPE
  • Cleveland BioLabs
  • Cobra Biomanufacturing
  • Consort Medical
  • Corden Pharmaceutical
  • Corvette
  • CPE Funds
  • Daiichi Sankyo
  • Daito Pharmaceutical
  • DBI
  • Delmas Perfusion
  • Delpharm
  • Divis Laboratories Ltd.
  • DPT Laboratories
  • DPX Holdings
  • Dr. Reddy's Laboratories Ltd.
  • Dragenopharm Apotheker Püschl
  • DSM Pharmaceutical Products(DPP)
  • Eagle Pharmaceuticals
  • Eclipse Therapeutics
  • Eisai
  • Ekkio Capital
  • Eli Lilly
  • EmulTech
  • Enzon Pharmaceuticals
  • Esteve Química
  • Euro Vital Pharma
  • Eurofins Amatsigroup
  • Euticals
  • Evonik
  • Exelixis
  • Famar Health Care Services
  • Fareva
  • Flamel Technologies
  • Frazier Healthcare
  • Fujifilm Diosynth Biotechnologies UK Ltd.
  • Gadea Pharmaceutical Group
  • Gallus BioPharmaceuticals
  • Genzyme
  • GlaxoSmithKline(GSK)
  • Hameln Pharmaceuticals GmbH
  • Hameln RDS GmbH
  • Haupt Pharma
  • Hospira, Inc.
  • Huapont Medical
  • Human Genome Sciences
  • Icagen, Inc.
  • Immune Pharmaceuticals
  • Immunomedics
  • Index Ventures
  • Indoco Remedies
  • Intellect Neurosciences
  • International Chemical Investors Group(ICIG)
  • IRIX Pharmaceuticals
  • Janssen
  • JK Pharmaceutical
  • JLL Partners
  • Johnson & Johnson(J&J)
  • KWS BioTest Limited
  • Laboratoire Aguettant
  • Laboratoires Besins
  • Lanxess Corporation
  • Lonza Group Ltd.
  • Lusomedicamenta
  • Madison Dearborn Partners, LLC(MDP)
  • Marine Ingredients
  • Marinopoulos Group
  • Merck KGaA
  • Mesoblast
  • Micron Technologies
  • Molecular Partners
  • Mundipharma
  • Mylan
  • New York Center for Nanomedicine Research(NYCNMR)
  • NIH CRM
  • Nikon
  • Nipro Corporation
  • Novozymes
  • Octane
  • OncoMed Pharmaceuticals
  • OPKO Health. Inc.
  • Opthea
  • Orpegen Peptide Chemicals GmbH
  • Osiris Therapeutics
  • Paragon Bioservices Inc
  • Patheon Inc
  • Pfizer
  • Pfizer CentreOne
  • Pfizer Inc./Pfizer CentreSource(PCS)
  • Pharmacia(now Pfizer)
  • Pharmacyclis
  • Pharmatek Laboratories, Inc.
  • Piramal
  • Piramal Healthcare L
  • Precision Ocular Ltd
  • Prime European Therapeuticals S.p.A
  • Progenics Pharmaceuticals
  • Propanc Health Group
  • Q-Biologicals
  • R5 Pharmaceuticals
  • Ranbaxy
  • Recipharm A
  • Regeneus
  • Relthy Laboratórios
  • Relypsa
  • Renaissance Acquisition Holdings, LLC
  • Rexim
  • Roche
  • Royal DSM
  • Sandoz
  • Sanofi
  • Schering(now Bayer)
  • Seattle Genetics
  • Sentry BioPharma Services
  • Servier
  • Shandong Tianda Biological Pharmaceutical
  • Shandong Xinhua Pharmaceutical
  • Siegfried
  • Sigma-Aldrich
  • Sigmar Italia
  • Sinopharm
  • Solasia Pharma
  • Solvay
  • Strides
  • SurModics
  • Swedish Orphan Biovitrium AB(Sobi)
  • Swiss Caps
  • Syntex(now Roche)
  • Takeda
  • Temmler Group
  • Tessenderlo Group
  • Teva
  • The Carlyle Group
  • Therapure Biopharma Inc.
  • TL Biopharmaceuticals Ltd
  • Tohoku Nipro Pharmaceutical Corporation
  • Tunitas Therapeutics
  • UCB
  • UMN Pharma
  • UPM Pharmaceuticals Inc.
  • Valerion Therapeutics
  • Vetter Pharmacuticals
  • Virbac
  • Whitehouse Analytical Laboratories, LLC.
  • WindRose
  • WuXi AppTec
  • Xcelience LLC
  • Xcellerex LLC
  • Xinhua Pharmaceutical(Gaomi) Company
  • XOMA
  • Yiwu Huayi Fine Chemical Co.
  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Huahai Pharmaceuticals
  • Zhejiang Jiang Yuan Tang
  • Zumutor
  • ZYMtronix

List of Organizations Mentioned in the Report:

  • Agence Nationale de sécurité du Médicament et des produits de santé(ANSM)
  • Agência Nacional de Vigilância Sanitária(ANVISA)
  • Biomedical Advanced Research and Development Authority(BARDA)
  • Cardinal Health Foundation
  • Eindhoven University of Technology
  • FDA
  • Générique Même Médicament(GEMME)
  • Health Canada
  • International Chemical Investors Group(ICIG)
  • MHRA
  • Queens University Belfast
  • Sanquin Blood Supply Foundation
  • University College London(UCL)
  • University of Bradford
  • University of Durham
  • University of Leeds
Back to Top